JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Home・Akcijų sąrašas・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25 -0.79

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.83

Max

25.33

Pagrindiniai rodikliai
By Trading Economics
Pajamos	675K 53M
Pardavimai	1.8M 148M
P/E Sektoriaus vid.	14.62 84.243
Pelno marža	35.57
Darbuotojai	181
EBITDA	1.7M 80M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+36% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-25

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	449M 3.1B
Ankstesnė atidarymo kaina	25.79
Ankstesnė uždarymo kaina	25

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

N/A / 24.28 Palaikymas ir pasipriešinimas

Catalyst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-04 22:55; UTC

Uždarbis

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

2026-02-04 21:44; UTC

Uždarbis

Arm Holdings 3Q Profit Falls Despite Revenue Growth

2026-02-04 21:39; UTC

Uždarbis

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

2026-02-04 23:46; UTC

Uždarbis

Arm Holdings Expects Slower Revenue Growth in 4Q -- Update

2026-02-04 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026-02-04 23:45; UTC

Karštos akcijos

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

2026-02-04 23:45; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

2026-02-04 23:32; UTC

Rinkos pokalbiai

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

2026-02-04 22:59; UTC

Įsigijimai, susijungimai, perėmimai

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

2026-02-04 22:30; UTC

Uždarbis

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

2026-02-04 22:30; UTC

Uždarbis

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

2026-02-04 22:21; UTC

Uždarbis

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026-02-04 22:17; UTC

Rinkos pokalbiai

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

2026-02-04 22:15; UTC

Rinkos pokalbiai

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

2026-02-04 22:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-02-04 21:53; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

2026-02-04 21:51; UTC

Uždarbis

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026-02-04 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-02-04 21:45; UTC

Uždarbis

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

2026-02-04 21:44; UTC

Uždarbis

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

2026-02-04 21:43; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

2026-02-04 21:41; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026-02-04 21:36; UTC

Rinkos pokalbiai

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

2026-02-04 21:30; UTC

Uždarbis

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026-02-04 21:30; UTC

Uždarbis

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026-02-04 21:30; UTC

Uždarbis

Beach Energy Interim Dividend 1 Australian Cent/Sjare

2026-02-04 21:30; UTC

Uždarbis

Steris Sees FY Adj EPS $10.15-Adj EPS $10.30 >STE

Akcijų palyginimas

Kainos pokytis

Catalyst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

36% į viršų

12 mėnesių prognozė

Vidutinis 34 USD 36%

Aukščiausias 35 USD

Žemiausias 33 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Catalyst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Catalyst Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 24.28Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.